RxDoctor Payments Data

Jennifer McKee

Family · Germantown, TNNPI 1841758059

Payments from drug & device makers

What this record shows

This record is dominated by other: $72,482 of the $80,996 with a category attached, or 89.5%. Convatec Inc. accounts for 89.5% of it on its own, with 44 other manufacturers making up the rest. 2025 is the largest year on record at $73,947, more than ten times the $807 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$80,996in general payments, 2019–2025

Across 313 payments — averaging $258.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$72K
  • Paratek Pharmaceuticals, Inc.$5K
  • AbbVie$403
  • Smith+Nephew$267
  • Ardelyx, Inc.$259
  • AstraZeneca$208
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$2,8804%
  • Travel & lodging$1090%
  • Food & beverage$5,5257%
  • Other$72,48289%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,996 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$365,041
Medicare patients
99
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.18$32,413
Naloxone Hcl301$24,385
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen451$13,803
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen579$9,581
Oxycodone Hcl235$5,439
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet26$1,194
Gentamicin Sulfate15$1,071
Diclofenac Sodium24$927
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip34$893
Gabapentin64$827
Nystatin28$560
Doxycycline Hyclate48$439
Pregabalin49$325
Clindamycin Hcl31$283
Tizanidine Hcl34$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$267$32,41318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →